A golden update for Touchstone, results out for Surgical and NPT Nets a 2 year contract

Wednesday, Apr 25 2012 by
1
Hybridan Small Cap Wrap
Hybridan Small Cap Wrap

A good week for the FTSE 100 which closed 100 points higher at 5,768 points thought the AIM All share closed where it opened at 781 points. Manufacturing pay in the UK was said to have risen by 2.6 per cent over the last 3 months, whilst Chinese manufacturing was also said to be on the mend. News also included UK retail sales having risen by 1.8 per cent in March and Unemployment was down by 35,000 in the period from December 2011 to February 2012. The week ahead sees public finances data, UK First Quarter GDP estimates and a variety of CBI Survey results being announced.

African Medical Investments (LON:AMEI) (LON:AMEI:1.88p/£6.04m)

African Medical Investments last week announced that the Company has raised US$375,000 by way of a subscription for loan notes by Harbinger Capital Partners Master Fund I Ltd under a newly constituted loan note instrument. The funds raised will be used to provide additional working capital which will be employed to consolidate the Company's position as a leading provider of high quality healthcare through private hospitals in Africa. As Harbinger is a substantial shareholder in African Medical, the issue of the Loan Notes constitutes a related party transaction under the AIM Rules for Companies.

Angle (LON:AGL) (LON:AGL 45.5p/£17.21m)

The technology commercialisation Company announced that it has achieved another important milestone by using its Parsortix cell separation device to successfully capture breast cancer circulating tumour cells (CTCs) in cancer patient blood. The Parsortix cancer diagnostic device has now been used to capture both prostate cancer CTCs and breast cancer CTCs in patient blood, the most common cancers in men and women respectively. In addition to prostate cancer and breast cancer, ANGLE has previously demonstrated that its Parsortix separation technology can capture cultured lung cancer, colon cancer and ovarian cancer cells added to blood (spiked blood). The new cancer patient blood finding is a further important step towards demonstrating that the Parsortix separation technology can capture any solid tumour cancers without the need for modification or dependence on cancer specific antibodies, unlike existing antibody affinity based technology. The development of the Parsortix separation technology is proceeding to plan and the next key milestones are: the validation of the separation device for other cancer types; the development…

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way

Disclaimer:  

This document should not be relied upon as being an impartial or objective assessment of the subject matter and is not deemed to be "independent research" for the purposes of the Financial Services Authority (FSA) rules. As a consequence the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).

The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual partners and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document.

This document has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.

In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties of Hybridan LLP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied up on by persons in the UK who are not relevant persons.

Neither this report nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor?s base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or PLUS Markets shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is Authorised and Regulated by the Financial Services Authority and is a member of the London Stock Exchange.


Hybridan LLP
29 Throgmorton Street, London EC2N 2AT

If you would like to receive other research reports from Hybridan, or would like to unsubscribe, please e- mail research@hybridan.com, title e-mail "research reports" or "unsubscribe me" Hybridan LLP is authorised and regulated by the Financial Services Authority Member of the London Stock Exchange


Do you like this Post?
Yes
No
1 thumb up
0 thumbs down
Share this post with friends



e2v technologies plc is engaged in providing image sensors and camera solutions. The Company operates through three segments: Imaging, RF Power and Semiconductors. The Imaging segment is providing imaging sensors, cameras and sub-systems for its customers across a range of applications in the automation, healthcare, discovery and environment markets. The RF Power segment is producing components and sub-systems that deliver radio frequency power generation for healthcare, industrial and defense applications. The Semiconductors segment is providing semiconductors that meet the demanding specifications of its customers. The Semiconductors segment also offers multi -chip modules and boards. The Company has approximately nine main engineering facilities and approximately six offices across Europe, the United States and Asia Pacific. The Company's subsidiaries include e2v technologies (UK) Limited, e2v technologies GmbH, e2v Limited, e2v technologies SAS, e2v semiconductors SAS and e2v SAS. more »

LSE Price
243p
Change
1.4%
Mkt Cap (£m)
523.6
P/E (fwd)
15.4
Yield (fwd)
2.5

Imperial Innovations Group PLC is a United Kingdom-based company that combines the activities of technology transfer, company incubation and investment. The Company sources and accesses technology from University College London, Oxford and Cambridge Universities, as well as Imperial College. It carries out market research to identify the product and market opportunity, assessing market need and the competition. It constructs a proof of concept strategy to demonstrate the performance and commercial potential of the technology. Then it determines the right commercialization strategy for a new technology. The Company works with the technology transfer offices for the University of Cambridge, the University of Oxford and University College London, as well as using a wider network of contacts to identify investment opportunities in early stage companies. more »

LSE Price
425p
Change
 
Mkt Cap (£m)
685.1
P/E (fwd)
n/a
Yield (fwd)
n/a



  Is E2V Technologies fundamentally strong or weak? Find out More »


What's your view on this article? Log In to Comment Now

You can track all @StockoChat comments via Twitter


About Hybridan

Hybridan

Hybridan is a corporate broker and PLUS markets corporate advisor specialising in fundraising, research and after-market support for small and micro cap companies. We utilise our market knowledge to provide creative financing solutions and strong after-market support. We build long term durable relationships with companies and investors, for the benefit of both. This long term approach, coupled with a high degree of selectivity, yields investments that outperform the market. more »



Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder